The c-Kit receptor belongs to type III tyrosine kinase receptor, which consists of an extracellular ligand binding domain and an intracellular kinase domain. In the kinase domain, the ATP binding site is separated from the phosphotransferase site by an interkinase sequence required for interaction with signal transduction proteins involved in the c-Kit pathway. 1 The c-Kit receptor is expressed in a wide variety of normal and neoplastic tissues. A positive correlation between misregulation of the c-kit gene and malignant transformation of cells has been reported. 2,3 For instance, substitution mutations in exon 11 of the gene, changing amino acids of the juxtamembrane region of the receptor, are associated with gastrointestinal stromal tumors, whereas mutations in exon 17 that substitute Asp816, just downstream of the tyrosine kinase signature, are associated with myeloid leukemias and testicular seminomas. 2,3 These mutations induce ligand-independent dimerization or autophosphorylation of the receptor and they cause constitutive activation of downstream signaling pathways. Moreover, overexpression of c-Kit and its ligand SCF occurs in several tumors and they probably stimulate proliferation in an autocrine or paracrine manner. 2 Recently, c-kit expression in various tumors has been revisited because this receptor is a target of the anti-cancer activity of a well described tyrosine kinase inhibitor: imatinib (STI1571). 2,4 Beside mutations affecting the activity of the full-length c-Kit, expression of an alternative transcript of human c-kit has been described in several transformed cell lines. The